biomodal Launches duet mosaic Giving Liquid Biopsy Researchers and Developers More Signal from Every Blood Draw
The duet mosaic family leverages a single-stranded ligation technology to resolve genetics, epigenetics and fragmentomics from the same cfDNA molecule in a streamlined, automation-ready workflow so teams can combine complementary signals for greater detection from precious, low-input samples
biomodal, an omics-based life sciences technology and analytics company, today announced the launch of the duet mosaic family, which includes two new circulating cell-free DNA (cfDNA)-optimized multiomic sequencing workflows for liquid biopsy and translational research. duet +modC mosaic and duet 6-base mosaic enable academic researchers, translational scientists, and assay developers to generate genetic, epigenetic and fragmentomic information from a single, precious sample in one integrated workflow.
The launch comes as the liquid biopsy and cfDNA research fields converge on a clear conclusion: no single signal is enough. Multi-signal approaches that combine methylation, fragmentomics and mutations consistently outperform any single modality for early cancer detection, minimal residual disease (MRD) detection and biomarker discovery. Data presented by biomodal at the European Association for Cancer Research (EACR) demonstrate the additive value of the approach: as independent signals are combined, classification improves and limits of detection fall, evidence that integrating complementary modes of information delivers more than any single measurement alone.
